China News Service, April 29 (Reporter Chen Jing) Shanghai Institute of Immunotherapy Innovation was inaugurated on the evening of the 29th at Renji Hospital, Shanghai Jiaotong University School of Medicine.
The Institute will be jointly established by the Shanghai Municipal People's Government and Shanghai Jiaotong University, actively exploring system and mechanism innovation, and building a world-class frontier immunotherapy research center and innovative immunotherapy research and development base.
It is understood that the institute integrates the advantages of basic immunology research and clinical immunology, deeply integrated into the overall development layout of Zhangjiang and Lingang National Laboratories, and uses immunology-related research as the starting point to focus on tumor immunotherapy, chronic inflammatory diseases and transplantation immunity. , Infectious diseases and vaccines, the three key research and development directions and application areas, and strive to build into a global influential immune innovation source, an introduction base for high-end and key talents in the immunology field, and a world-class immunology basic innovation to industrial applications Conversion base.
The Shanghai Institute of Immunotherapy Innovation was unveiled.
Photo courtesy of Renji Hospital
Dong Chen, academician of the Chinese Academy of Sciences and the first dean of the Shanghai Institute of Immunotherapy Innovation, believes that strengthening innovative research on immunotherapy will continue to increase the global influence of the Shanghai Science and Technology Innovation Center, accelerate the development of the biomedical industry, and better protect the people. Life and health have very important meanings.
Fan Xianqun, Dean of Shanghai Jiaotong University School of Medicine, said that immunology, as a frontier subject of life sciences, is closely related to the prevention and treatment of major diseases such as tumors, infections, metabolism, and aging itself. Every major breakthrough in immunology will give birth to the medical and biomedical industries. Leapfrog development.
It is reported that the Institute will establish a council and a high-level academic committee to initiate and promote the physical construction of the Institute.
According to reports, the Institute will also focus on the connection with the biomedical industry and accelerate the transformation and application of results, so as to promote the high-quality development of Shanghai's biomedical industry and enhance its leading position and influence in the global biomedical innovation system.
On behalf of the Shanghai Municipal People’s Government, Zong Ming and Shanghai Jiao Tong University’s Party Secretary Yang Zhenbin signed an agreement to jointly build Shanghai Immunotherapy Innovation Research Institute. On behalf of the Shanghai Municipal People’s Government, Zong Ming and Shanghai Jiao Tong University’s Party Secretary Yang Zhenbin signed an agreement to jointly build Shanghai. Agreement of the Institute of Immunotherapy Innovation.
Wu Qing, member of the Standing Committee of the Shanghai Municipal Party Committee and Deputy Mayor, hopes that the institute will focus on the national strategic needs and benchmark against the international advanced level; introduce a team of high-level scientists to create a highland of immunology talents; at the same time, deepen the reform of the system and mechanism and enhance the efficiency of innovation.
On the same day, Carola Vinuesa, academician of the Australian Academy of Sciences, academician of the Australian Academy of Medical Sciences, professor of immunology at the Australian National University, and co-director of the Australian side of the China-Australia Center for Individualized Immunology, sent a congratulatory video. She said that she is very willing to participate in the future major projects of the Institute, and cooperate with the members of the Institute, and work together to alleviate the suffering of incurable immune diseases in China and the world. (Finish)Keywords: